Kamada Pharmaceuticals - Company Profile
Powered by 
All the data and insights you need on Kamada Pharmaceuticals in one report.
$295
- Save hours of research time and resources with
our up-to-date Kamada Pharmaceuticals Strategy Report
- Understand Kamada Pharmaceuticals position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kamada Pharmaceuticals (Kamada), is a biopharmaceutical company that develops, manufactures, and commercializes specialty proteins, specific immunoglobulins, and other prescription medicines. Its major products include respiratory, immunoglobins, critical care, and others. It also offers medicines for the treatment of cystic fibrosis, asthma, hemophilia, rabies, hepatitis B and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes, covid-19, and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India, and other countries in Eastern Europe, Latin America, and Asia regions. Kamada is headquartered in Rehovot, Israel.
Headquarters
Israel
Address
2 Holtzman St., Science Park, Rehovot, 7670402
Website
www.kamada.com
Telephone
972 8 9406472
No of Employees
378
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KMDA (NASD)
Revenue (2022)
$142.5M
10.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
456.9%
(2022 vs 2021)
Market Cap*
$322.4M
Net Profit Margin (2022)
XYZ
424.6%
(2022 vs 2021)
* As of and is in US$
Kamada Pharmaceuticals premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Aerobika |
| Inhaled AAT- AAT Deficiency | Respikam |
| Recombinant AAT- AAT Deficiency | Glassia |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with Kedrion Biopharma Ltd to combat Rabies and other potentially fatal illnesses and circumstances. |
| 2023 | Contracts/Agreements | In July, the company extended its distribution agreement with Kedrion for KEDRAB for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. |
| 2022 | Contracts/Agreements | In November, the company signed an agreement with AcuCort AB under which Kamada secure the exclusive right to the marketing and sales as well as the distribution of AcuCort’s drug Zeqmelit. |
Competitor Comparison
| Key Parameters | Kamada Pharmaceuticals | Takeda Pharmaceutical Co Ltd | CSL Ltd | Grifols SA | Alnylam Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Israel | Japan | Australia | Spain | United States of America |
| City | Rehovot | Chuo-Ku | Melbourne | Barcelona | Cambridge |
| State/Province | - | Tokyo | Victoria | Barcelona | Massachusetts |
| No. of Employees | 378 | 49,095 | 32,065 | 23,744 | 2,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lilach Asher Topilsky | Chairman | Executive Board | 2020 | 51 |
| Amir London | Chief Executive Officer | Senior Management | 2015 | 54 |
| Chaime Orlev | Chief Financial Officer | Senior Management | 2017 | - |
| Eran Nir | Chief Operating Officer | Senior Management | 2022 | 50 |
| David Tsur | Deputy Chairman | Non Executive Board | 2015 | 72 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer